A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer

CONCLUSION: The patients of non-intestinal type GC may benefit from the SOX regimen. Differences were counted without being statistically significant with intestinal-type GC in the SOX or XELOX groups.PMID:37767800 | DOI:10.2174/0115665232247694230921060213

Source: Current Gene Therapy - September 28, 2023 Category: Genetics & Stem Cells Authors: Ke Wang Yuanyuan Yu Jian Zhao Qianhao Meng Chang Xu Jing Ren Yanqiao Zhang Yusheng Wang Guangyu Wang Source Type: research